Professor Reilly has extensive experience guiding life science projects, portfolios and investment decisions. He advises biotechs, VCs, medical charities, academics, and was on the 2014 REF committee. He is a Professor of Practice at KCL and a Board member of the Medicines Discovery Catapult, Salford Royal NHS Foundation Trust and Pennine Acute Care NHS Trust.
He was Global VP and Head of Project Evaluation at AstraZeneca from 2005 to 2011. He was also responsible for developing AZ’s research strategy, business plan and performance improvement activities. He was a member of the senior R&D Leadership team and the Committee that selected compounds for clinical development. He worked at the healthcare VC, Advent International (Boston), from 2003 to 2005. Dr Reilly joined the pharmaceutical industry in 1987 working first at Merck (USA) and then Zeneca (1993, UK) where he was VP, Respiratory and Inflammation Research at AZ from 1999 to 2003. He has a PhD from the University of Georgia and did post-doctoral work at MIT.